临床前3D模型筛选发现地高辛可有效治疗一种罕见且侵袭性强的子宫内膜癌
本研究针对SWI/SNF复合物失活型去分化子宫内膜癌(DDEC)建立患者肿瘤来源的3D球状体模型,通过高通量药物再利用筛选发现地高辛和洋地黄毒苷为候选药物;体外剂量反应分析显示两种药物在DDEC细胞中的IC50低于非DDEC子宫内膜癌细胞,体内异种移植模型中地高辛在临床相关血清浓度下显著抑制DDEC肿瘤生长。
要点
- 在DDEC细胞系3D球状体模型中高通量筛选发现地高辛和洋地黄毒苷为候选药物。
- 体外剂量反应分析显示地高辛和洋地黄毒苷在DDEC细胞中的IC50低于非DDEC子宫内膜癌细胞。
- 体内异种移植模型中地高辛在临床相关血清浓度下显著抑制DDEC肿瘤生长。
核心结论
- 研究利用患者肿瘤样本来源的DDEC临床前模型,发现地高辛可有效抑制DDEC肿瘤生长。
- 这些发现为地高辛作为SWI/SNF失活型DDEC的系统性治疗提供了有力的临床前证据,可能也适用于其他SWI/SNF失活型肿瘤。
研究设计与样本
- 研究建立了DDEC细胞系(SMARCA4失活的DDEC-1和ARID1A/ARID1B共失活的DDEC-2)的体外3D球状体模型并进行高通量药物再利用筛选。
- 对筛选出的候选药物进行体外剂量反应关系评估,随后使用DDEC-1和DDEC-2异种移植模型进行体内评估。
主要发现
- 3D模型药物筛选在DDEC-1和DDEC-2中均鉴定出包括地高辛和洋地黄毒苷在内的多种强心苷类候选药物。
- 体外剂量反应分析证实地高辛和洋地黄毒苷具有抑制活性,两种药物在DDEC细胞中的IC50均低于非DDEC子宫内膜癌细胞。
- 在体内异种移植模型中,地高辛在临床相关血清浓度下显著抑制DDEC肿瘤生长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Dedifferentiated endometrial carcinoma (DDEC) characterized by SWItch/Sucrose Non-Fermentable (SWI/SNF) complex inactivation is a highly aggressive type of endometrial cancer without effective systemic therapy options. Its uncommon nature and aggressive disease trajectory pose significant challenges for therapeutic progress. To address this obstacle, we focused on developing preclinical models tailored to this tumor type and established patient tumor-derived three-dimensional (3D) spheroid models of DDEC. METHODS: High-throughput drug repurposing screens were performed on in vitro 3D spheroid models of DDEC cell lines (SMARCA4-inactivated DDEC-1 and ARID1A/ARID1B co-inactivated DDEC-2). The dose-response relationships of the identified candidate drugs were evaluated in vitro, followed by in vivo evaluation using xenograft models of DDEC-1 and DDEC-2. RESULTS: Drug screen in 3D models identified multiple cardiac glycosides including digoxin and digitoxin as candidate drugs in both DDEC-1 and DDEC-2. Subsequent in vitro dose-response analyses confirmed the inhibitory activity of digoxin and digitoxin with both drugs showing lower IC50 in DDEC cells compared to non-DDEC endometrial cancer cells. In in vivo xenograft models, digoxin significantly suppressed the growth of DDEC tumors at clinically relevant serum concentrations. CONCLUSION: Using biologically precise preclinical models of DDEC derived from patient tumor samples, our study identified digoxin as an effective drug in suppressing DDEC tumor growth. These findings provide compelling preclinical evidence for the use of digoxin as systemic therapy for SWI/SNF-inactivated DDEC, which may also be applicable to other SWI/SNF-inactivated tumor types.
引用
- Kumar PP, Smith D, Key J, et al. Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer. Gynecol Oncol. 2024. PMID: 38970843. doi:10.1016/j.ygyno.2024.06.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。